Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years, male or female;~2. Histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC):~   * Patients scheduled to receive carboplatin plus etoposide regimen: no prior systemic therapy (eg, chemotherapy or combined with immunotherapy);~  * Patients scheduled to receive topotecan regimen: previously received 1/2 lines of chemotherapy or combined immunotherapy but not topotecan.~3. Presence of at least one radiation-naïve measurable lesion according to RECIST 1.1 criteria;~4. Hemoglobin ≥ 90 g/L;~5. Neutrophil count ≥ 1.5 × 10\^9/L;~6. Platelet count ≥ 100 × 10\^9/L;~7. Creatinine ≤ 15 mg/L or creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault formula);~8. Total bilirubin ≤ 1.5 × upper limit of normal (ULN);~9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN or ≤ 5 × ULN (for patients with liver metastases);~10. Albumin ≥ 30 g/L;~11. ECOG PS score 0 - 2;~12. Expected survival time ≥ 3 months;~13. Contraception:~    Females: All females of childbearing potential must have a negative serum pregnancy test at screening and must use reliable contraception from signing of informed consent through 3 months after the last dose; Male: Female partners of childbearing potential must use reliable contraception from signing the informed consent until 3 months after the last dose;~14. Understand and sign informed consent~Exclusion Criteria:~1. Symptomatic brain metastases requiring local radiotherapy or hormonal therapy;~2. History of other malignancies, with the following exceptions: (1) clinically cured cutaneous basal cell or squamous cell tumors; (2) cured a) cervical cancer, b) prostate cancer, c) superficial bladder cancer; or (3) other solid tumors with a clinical cure time of more than 3 years;~3. Uncontrolled ischemic heart disease or clinically significant congestive heart failure (NYHA Class III or IV);~4. Stroke or cardiovascular or cerebrovascular event within 6 months prior to enrollment;~5. Severe active infection;~6. Psychological or other social factors causing insufficient trial compliance;~7. Other uncontrolled serious chronic diseases or conditions that, in the opinion of the investigator, would make participation in the trial inappropriate;~8. Known HIV infection, active hepatitis B (defined as positive HBV DNA), and hepatitis C (positive HCV RNA);~9. Radiation therapy within 2 weeks prior to enrollment;~10. Patients who have received cytotoxic drug therapy or investigational drug therapy within 4 weeks before enrollment, or non-cytotoxic anti-tumor drug therapy within 2 weeks;~11. Subjects in the first part of the study should not take strong or moderate inducers of CYP3A4 concomitantly within 4 weeks before taking the study drug, and strong inhibitors of CYP3A4 concomitantly within 2 weeks before taking the study drug;~12. Toxicity from prior anticancer therapy has not recovered to Grade 0 or 1 (except alopecia);~13. Hypersensitivity to the study drug (Trilaciclib, etoposide, carboplatin, topotecan) or components thereof;~14. Persons who are unable to act independently due to legal restriction or legal sense;~15. Pregnant or lactating women;~16. Not suitable for participating in this study in the investigator 's opinion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part I ( Safety run-in and PK Evaluation); Trilaciclib Group (Type: ACTIVE_COMPARATOR): 12 patients( 6 patients are first line, 6 patients are second or third line) recieved Trilaciclib(240mg/m\^2) plus chemotherapy.
- Part II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib Group (Type: ACTIVE_COMPARATOR): 41 patients received trilaciclib(240mg/m\^2) plus chemotherapy
- Part II ( Randomized Double-blind, Placebo-controlled ), Placebo Group (Type: PLACEBO_COMPARATOR): 42 patients received placebo plus chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).